Annual Cash & Cash Equivalents
$771.74 M
+$431.29 M+126.68%
December 31, 2024
Summary
- As of March 14, 2025, NAMS annual cash & cash equivalents is $771.74 million, with the most recent change of +$431.29 million (+126.68%) on December 31, 2024.
- During the last 3 years, NAMS annual cash & cash equivalents has risen by +$711.63 million (+1183.84%).
- NAMS annual cash & cash equivalents is now at all-time high.
Performance
NAMS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$771.74 M
+$349.01 M+82.56%
December 31, 2024
Summary
- As of March 14, 2025, NAMS quarterly cash and cash equivalents is $771.74 million, with the most recent change of +$349.01 million (+82.56%) on December 31, 2024.
- Over the past year, NAMS quarterly cash and cash equivalents has increased by +$349.01 million (+82.56%).
- NAMS quarterly cash and cash equivalents is now at all-time high.
Performance
NAMS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
NAMS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +126.7% | +82.6% |
| 3 y3 years | +1183.8% | +82.6% |
| 5 y5 years | +7881.9% | +82.6% |
NAMS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +1183.8% | at high | +1183.8% |
| 5 y | 5-year | at high | +7881.9% | at high | +1183.8% |
| alltime | all time | at high | +7881.9% | at high | +1183.8% |
NewAmsterdam Pharma Company NV Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $771.74 M(+126.7%) | $771.74 M(+82.6%) |
| Sep 2024 | - | $422.73 M(-1.9%) |
| Jun 2024 | - | $430.71 M(-10.5%) |
| Mar 2024 | - | $481.15 M(+41.3%) |
| Dec 2023 | $340.45 M | $340.45 M(-18.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $416.76 M(-10.9%) |
| Dec 2022 | $467.73 M(+678.1%) | $467.73 M(+400.4%) |
| Jun 2022 | - | $93.47 M(+55.5%) |
| Dec 2021 | $60.11 M(+521.7%) | $60.11 M |
| Dec 2020 | $9.67 M | - |
FAQ
- What is NewAmsterdam Pharma Company NV annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NewAmsterdam Pharma Company NV?
- What is NewAmsterdam Pharma Company NV annual cash & cash equivalents year-on-year change?
- What is NewAmsterdam Pharma Company NV quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NewAmsterdam Pharma Company NV?
- What is NewAmsterdam Pharma Company NV quarterly cash and cash equivalents year-on-year change?
What is NewAmsterdam Pharma Company NV annual cash & cash equivalents?
The current annual cash & cash equivalents of NAMS is $771.74 M
What is the all time high annual cash & cash equivalents for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV all-time high annual cash & cash equivalents is $771.74 M
What is NewAmsterdam Pharma Company NV annual cash & cash equivalents year-on-year change?
Over the past year, NAMS annual cash & cash equivalents has changed by +$431.29 M (+126.68%)
What is NewAmsterdam Pharma Company NV quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NAMS is $771.74 M
What is the all time high quarterly cash and cash equivalents for NewAmsterdam Pharma Company NV?
NewAmsterdam Pharma Company NV all-time high quarterly cash and cash equivalents is $771.74 M
What is NewAmsterdam Pharma Company NV quarterly cash and cash equivalents year-on-year change?
Over the past year, NAMS quarterly cash and cash equivalents has changed by +$349.01 M (+82.56%)